Innate barriers against skin infection and associated disorders

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 2, 2008, Pages

  Gallo, Richard L ^a   Nizet, Victor ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PEPTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TETRACYCLINE; VITAMIN D; VITAMIN D DERIVATIVE;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIGEN ANTIBODY REACTION; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SYNTHESIS; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; LEUKOCYTE FUNCTION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; NECROTIZING FASCIITIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; SKIN EPITHELIUM; SKIN INFECTION; SKIN INFLAMMATION; SKIN PROTECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; TRANSCRIPTION REGULATION;

EID: 67349189165     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.04.009     Document Type: Review

References (64)

1. Shouche Y.S., and Patole M.S. Microbial diversity: no limits?. Curr. Sci. 88 (2005) 1370-1371
2. Taylor K.R., et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on TLR4, CD44 and MD-2. J. Biol. Chem. (2007)
3. Takeuchi O., and Akira S. Signaling pathways activated by microorganisms. Curr. Opin. Cell Biol. 19 (2007) 185-191
4. Meylan E., et al. Intracellular pattern recognition receptors in the host response. Nature 442 (2006) 39-44
5. Hu X., et al. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J. Leukoc. Biol. 82 (2007) 237-243
6. Schauber J., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117 (2007) 803-811
7. Liu P.T., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006) 1770-1773
8. Weck M.M., et al. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 109 (2007) 3890-3894
9. Radek K., and Gallo R. Antimicrobial peptides: natural effectors of the innate immune system. Semin. Immunopathol. 29 (2007) 27-43
10. Dorschner R.A., et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117 (2001) 91-97
11. Schauber J., et al. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118 (2006) 509-519
12. Selsted M.E., et al. Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. Infect. Immun. 45 (1984) 150-154
13. Henzler Wildman K.A., et al. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 42 (2003) 6545-6558
14. Oppenheim J.J., and Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17 (2005) 359-365
15. De Y., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192 (2000) 1069-1074
16. Tjabringa G.S., et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171 (2003) 6690-6696
17. Di Nardo A., et al. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 178 (2007) 1829-1834
18. Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr. Opin. Gastroenterol. 21 (2005) 147-151
19. Nizet V., et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414 (2001) 454-457
20. Huang L.C., et al. Cathelicidin-deficient (Cnlp-/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4498-4508
21. Iimura M., et al. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 174 (2005) 4901-4907
22. Chromek M., et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12 (2006) 636-641
23. Bergman P., et al. Induction of the antimicrobial peptide CRAMP in the blood brain barrier and meninges after meningococcal infection. Infect. Immun. (2006)
24. Lee P.H., et al. From the cover: expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3750-3755
25. Bals R., et al. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Invest. 103 (1999) 1113-1117
26. Giacometti A., et al. The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit. Care Med. 32 (2004) 2485-2490
27. McPhee J.B., et al. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50 (2003) 205-217
28. Bader M.W., et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 122 (2005) 461-472
29. Peschel A., et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193 (2001) 1067-1076
30. Peschel A., et al. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274 (1999) 8405-8410
31. Kristian S.A., et al. MprF-mediated lysinylation of phospholipids in Staphylococcus aureus leads to protection against oxygen-independent neutrophil killing. Infect. Immun. 71 (2003) 546-549
32. Kristian S.A., et al. Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. J. Infect. Dis. 188 (2003) 414-423
33. Kupferwasser L.I., et al. Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. Antimicrob. Agents Chemother. 43 (1999) 2395-2399
34. Sieprawska-Lupa M., et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48 (2004) 4673-4679
35. Ulvatne H., et al. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol. Lett. 237 (2004) 377-384
36. Jin T., et al. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172 (2004) 1169-1176
37. Braff M.H., et al. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J. Infect. Dis. 195 (2007) 1365-1372
38. Clarke S.R., et al. The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin. Cell Host Microbe 1 (2007) 199-212
39. Li M., et al. Gram-positive three-component antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9469-9474
40. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 8 (2006) 11-26
41. Kristian S.A., et al. d-Alanylation of teichoic acids promotes group a Streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J. Bacteriol. 187 (2005) 6719-6725
42. Schmidtchen A., et al. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 46 (2002) 157-168
43. Nyberg P., et al. alpha2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J. Biol. Chem. 279 (2004) 52820-52823
44. Kwinn L.A., et al. Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin s operon in invasive M1T1 group A Streptococcus. J. Bacteriol. 189 (2007) 1322-1329
45. Fernie-King B.A., et al. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology 111 (2004) 444-452
46. Fernie-King B.A., et al. Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. Microbes Infect. 9 (2007) 300-307
47. Brinkmann V., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004) 1532-1535
48. Buchanan J.T., et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16 (2006) 396-400
49. Walker M.J., et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat. Med. 13 (2007) 981-985
50. Marodi L., and Notarangelo L.D. Immunological and genetic bases of new primary immunodeficiencies. Nat. Rev. Immunol. 7 (2007) 851-861
51. Leung D.Y. Infection in atopic dermatitis. Curr. Opin. Pediatr. 15 (2003) 399-404
52. Palmer C.N., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38 (2006) 441-446
53. Ong P.Y., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347 (2002) 1151-1160
54. Howell M.D., et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin. Immunol. 121 (2006) 332-338
55. Howell M.D., et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172 (2004) 1763-1767
56. Conner K., et al. The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J. Am. Acad. Dermatol. 47 (2002) 347-350
57. Buck C.B., et al. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1516-1521
58. Ingraham B.A., et al. Molecular basis of the potential of vitamin D to prevent cancer. Curr. Med. Res. Opin. 24 (2008) 139-149
59. Yamasaki K., et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20 (2006) 2068-2080
60. Yamasaki K., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 13 (2007) 975-980
61. Frohm M., et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272 (1997) 15258-15263
62. Marchini G., et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br. J. Dermatol. 147 (2002) 1127-1134
63. Lande R., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007) 564-569
64. Zinkernagel A.S., et al. Pharmacologic augmentation of hypoxia-inducible factor-1alpha with mimosine boosts the bactericidal capacity of phagocytes. J. Infect. Dis. 197 (2008) 214-217